A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.

Trial Profile

A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms MILES-4
  • Most Recent Events

    • 14 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
    • 06 Jun 2017 A joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies (from Mar 2011 to Aug 2016, 531 patients) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 27 Mar 2017 Planned number of patients changed from 550 to 231.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top